SELLAS Life Sciences Group, Inc. (SLS)
11.74
+0.41
(+3.62%)
USD |
NASDAQ |
Oct 02, 16:00
11.75
+0.01
(+0.09%)
After-Hours: 20:00
SELLAS Life Sciences Group Net Income (Quarterly) : -9.605M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -9.605M |
| March 31, 2026 | -8.407M |
| December 31, 2025 | -7.658M |
| September 30, 2025 | -6.791M |
| June 30, 2025 | -6.601M |
| March 31, 2025 | -5.813M |
| December 31, 2024 | -6.737M |
| September 30, 2024 | -7.108M |
| June 30, 2024 | -7.47M |
| March 31, 2024 | -9.566M |
| December 31, 2023 | -8.136M |
| September 30, 2023 | -9.267M |
| June 30, 2023 | -8.84M |
| March 31, 2023 | -11.10M |
| December 31, 2022 | -9.121M |
| September 30, 2022 | -7.022M |
| June 30, 2022 | -8.414M |
| March 31, 2022 | -16.74M |
| December 31, 2021 | -6.598M |
| September 30, 2021 | -7.085M |
| June 30, 2021 | -4.613M |
| March 31, 2021 | -2.403M |
| December 31, 2020 | -3.716M |
| September 30, 2020 | -4.473M |
| June 30, 2020 | -4.425M |
| Date | Value |
|---|---|
| March 31, 2020 | -4.143M |
| December 31, 2019 | 0.997M |
| September 30, 2019 | -11.47M |
| June 30, 2019 | -4.086M |
| March 31, 2019 | -4.976M |
| December 31, 2018 | -13.32M |
| September 30, 2018 | -0.781M |
| June 30, 2018 | -8.53M |
| March 31, 2018 | -9.963M |
| December 31, 2017 | -8.177M |
| September 30, 2017 | -4.455M |
| June 30, 2017 | -5.913M |
| March 31, 2017 | -4.601M |
| December 31, 2016 | -1.935M |
| September 30, 2016 | -4.342M |
| June 30, 2016 | 8.278M |
| March 31, 2016 | -13.10M |
| December 31, 2015 | -10.81M |
| September 30, 2015 | -6.352M |
| June 30, 2015 | -15.66M |
| March 31, 2015 | -10.54M |
| December 31, 2014 | -7.956M |
| September 30, 2014 | -6.173M |
| June 30, 2014 | -19.94M |
| March 31, 2014 | -2.536M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| AbbVie, Inc. | 3.604B |
| Capricor Therapeutics, Inc. | -40.73M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Incyte Corp. | 585.60M |
| Insmed, Inc. | -13.24M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 9.605M |
| EPS Diluted (Quarterly) | -0.0508 |
| Enterprise Value | 2.233B |
| Earnings Yield | -1.81% |
| Normalized Earnings Yield | -1.808 |